Sapience Therapeutics, Inc.
Franco Abbate currently serves as the Director of Translational Sciences at Sapience Therapeutics, Inc., where responsibilities include developing strategies for identifying biomarkers and managing pharmacodynamics studies. Prior to this role, Franco held the position of Director of Pharmacology and Immuno-Oncology Research at Intensity Therapeutics, Inc., leading preclinical projects and designing immunotherapy strategies. Earlier experience includes a role as Scientist II in vivo Pharmacology at Atreca, Inc., where in vivo tumor studies were developed, and a postdoctoral research fellowship at Mount Sinai Health System, focusing on the biological functions related to tumor biology and mentoring. Franco began the academic journey as a PhD student at Policlinico Umberto I, studying molecular aspects of melanoma.
This person is not in any teams
This person is not in any offices
Sapience Therapeutics, Inc.
1 followers
Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme(GBM), which is the most severe and deadly form of brain cancer.The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States.